Madrid. NTC, an Italian pharmaceutical company, has announced the acquisition of a product portfolio in the ophthalmic sector from Novartis – a multinational leader based in Switzerland operating in the pharmaceutical sector. NTC, controlled by Wise SGR through the Italian private equity fund Wisequity III, thanks to this transaction, has further strengthened its product range in the ophthalmic area, particularly in Spain (but also in Italy, Portugal, and Poland), where the company intends to launch its own network of scientific informers – as has already successfully occurred in Italy in 2017 – to directly promote more products currently under development. Novartis products acquired from NTC include: Colircusi Gentadexa, Colircusi Gentamicin and Oftalmolosa Cusi Gentamicina (aminoglycoside), Oftalmolosa Cusi Erythromycin (macrolide), Oftalmolosa Cusi Aureomycin (tetracycline), and Oftacilox (fluoroquinolone). (9Colonne)
